GlaxoSmithKline Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

GlaxoSmithKline Case Solution

Glaxo's CEDD model

The GlaxoSmithKline Centers of Excellence in Drug Discovery is clearly an important step forward for the company's R&D. The company's new CEO has a strong commitment to science and innovation. With its new focus on collaboration, the company is increasingly leveraging the strengths of other companies to achieve its goals. The little size of the CEDDs would likewise permit researchers to have different announcing connections than those in the legacy firms and at GSK's rivals. Yamada noticed: Almost every medication organization has made multidisciplinary R&D groups centered by helpful region. That is the manner by which medications are made. The CEDDs will be quite uniquely as it will use to convert a matrix into the series of reporting line relationships. In this model, scientists and scholars will never again answer to worldwide practical regions; they will answer to the CEDDs.(Pisano, 2011)

Wyeth'snew way of working model

The change to the company's New Way of working model has been a long time coming. Andrew Wyeth told Thomas Having, an associate professor at the University of Delaware, that he went to the Helga paintings for emotional power. He wanted this same emotional power in his public work. In 1976, he showed a series of Helga paintings at the Metropolitan Museum of Art. Andrew Ruffolo, Wyeth's chief operating officer, reorganized the company's drug discovery function. By taking lessons from non-pharmaceutical manufacturing, Ruffolo was able to restructure Wyeth's research and development department and make it more efficient. The result was a more productive organization and a more profitable organization. The New Way of working model has proved to be a successful strategy in helping the company to reach its financial goals.(O'Brien, 2006)

CEDD Model vs Wyeth new way of working model

The centers of excellence in drug development (CEDD) model at GlaxoSmithKline and Wyeth Pharmaceuticals are similar. They both see the R&D process as a collaborative effort and are focused on spurring creativity. The two companies differ slightly in the types of projects they fund and the types of metrics they use. However, the fundamentals of their approaches to drug development are similar.Unlike Wyeth, Glaxo Wellcome has a better track record in oncology. Scientists at Glaxo's CED were the first to discover a promising breast cancer compound, Tykerb. Rather than focusing on the development of a cancer drug, Glaxo's scientists scrapped other projects in order to focus on Tykerb, a potential breast cancer drug. The company is hoping to submit Tykerb for FDA approval next year.

While Wyeth has a better portfolio in oncology drugs, Glaxo's focuses on oncology. In fact, Glaxo has a more robust pipeline, which includes small molecules and vaccines. In the future, partnerships with universities and other organizations focused on early-stage discovery will be essential. In the meantime, Wyeth has partnered with Janssen Alzheimer Immunotherapy Research and Development, a subsidiary of Johnson & Johnson.

The difference between these two companies can be seen in the early stages of drug discovery. GSK's Centers of Excellence for Drug Discovery has a greater focus on early-stage research, which could be indicative of improved productivity. In addition, these centers of excellence have more collaborations with universities and non-profit organizations, enabling researchers to focus on early-stage discovery.............................

This is just a sample partial case solution. Please place the order on the website to order your own originally done case solution.